contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Zeidan presented this data at ASH 2025. https://forum.inderes.com/t/faron-pharmaceuticals-innovatiivisia-laaketieteen-ratkaisuja-osa-2/66933/2123

https://nordiclifescience.org/finns-fighting-cancer-a-small-nation-with-global-impact/ Finns Fighting Cancer – A Small Nation with Global Impact Not just praise for Finland / Faron, but a slightly broader company overview.

And additionally, major shareholders’ holdings increased last month. A very good direction!

In the Faron/Juho webcast, a slide was presented that addressed partnering strategy with “enhanced management team and collaboration with a leading investment bank”. JPM has not been named. Faron Pharmaceuticals - Innovatiivisia lääketieteen ratkaisuja (Osa 1) - #10936 käyttäjältä Vino_Pino In itself, participating in JPM is the most significant of the calendar meetings previously compiled in the thread, in terms of partnering. Everyone will certainly be there. Those who already know they are a partner, and those who don’t know it yet. It’s likely improbable that a deal would be announced right then. In Stubb’s words, the (peace) agreement is closer than ever. It can’t exactly get any further away, if and when it is eventually signed…

282 new owners for Faron in two days on Nordnet alone:  After today, the figure will likely be 400, and by doubling that, we get roughly the number of new retail investors in three days. Kauppalehti’s marketing as the “gainer of the year” is doing its job, and the share price development still relies on retail investors’ buying appetite; hopefully, everyone participating in the lottery wins.

Since the wise heads of this forum still seem to be on holiday, I took the liberty of asking my own expert, who is an AI but not ChatGPT:  New information: Differentiation by TP53 mutation status  This is the most significant new piece of information. Previously, Faron has spoken about responses more broadly, but here they have been broken down by TP53 gene mutation:   Treatment-naïve (new patients):   91 % ORR (wt TP53, i.e., wild-type/normal gene). This is a staggering figure.   78 % ORR (mTP53, i.e., mutated gene). This is the “difficult” patient group for which there are currently no good treatments. The fact that even in this group we are reaching nearly 80 percent is a very strong medical result.   Biallelic ORR: 83 %. This is very specific data on the most difficult form of mutation.     2. New information: R/R MDS (relapsed/refractory) It was previously known that responses in R/R patients are lower, but here it is now in black and white:   74 % ORR (wt TP53). This is a very competitive figure in this difficult patient group.   46 % ORR (mTP53). Although the figure is lower than in new patients, it is still significant because the prognosis for R/R mTP53 patients has traditionally been very poor.   My “expert” explained that data as being so good from an investor’s perspective that I don’t dare add it here.

Since it’s quiet on the forum, we could take a look at the information on the Zeidan/HCPLive site: A total of 21 treatment-naïve and 32 HMA r/r MDS patients have been recruited into BEXMAB – bexmarilimab 1-6 mg/kg in phase 1 and 3 or 6 mg/kg in phase 2 was administered weekly in 28-day cycles in combination with a standard regimen of azacitidine. Preliminary overall response rates (ORR) with bexmarilimab and azacitidine in treatment-naïve patients were 78% in mTP53 (biallelic ORR: 83%) and 91% in wt TP53. In r/r MDS, preliminary ORR were 46% in mTP53 (biallelic ORR: 38%) and 74% in wt TP53.2 Is there actually new information here, or is old information just being expressed in a different way? I couldn’t quite tell from a quick look.

Faron Pharmaceuticals

Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk ...

<p>Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk investment as drug development requires frontloaded investments in research, while the success of commercialization is very uncertain. If the drug candidates enter the market, the invested capital can be multiplied. However, failure of drug development is frequent and, in that case, the invested capital may be partially or totally lost. We believe the share provides sufficient expected return to counterbalance the high risk. The share is suitable for a long-term investor that tolerates high risk as part of a well-diversified portfolio. A person investing in Faron must also be prepared for share issues.</p> 

	2021	22e	23e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-21.1	-22.0	-0.8
EBIT-% (adj.)	-527,700.0 %	-550,000.0 %	-19,500.0 %
EPS (adj.)	-0.40	-0.40	-0.02
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Risky investment with huge potential

Key Estimate Figures2022-08-08

Forum discussions